Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial

Klaus Rasmussen; Michael Maeng; Anne Kaltoft; Per Thayssen; Henning Kelbaek; Hans Henrik Tilsted; Ulrik Abildgaard; Evald Høj Christiansen; Thomas Engstrøm; Lars Romer Krusell; Jan Ravkilde; Peter Riis Hansen; Knud Nørregaard Hansen; Steen Zabell Abildstrøm; Jens Aarøe; Jan Skov Jensen; Steen Dalby Kristensen; Hans Erik Bøtker; Morten Madsen; Søren Paaske Johnsen; Lisette Okkels Jensen; Henrik Toft Sørensen; Leif Thuesen; Jens Flensted Lassen; SORT OUT III study group

doi:10.1016/S0140-6736(10)60208-5

Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial

Klaus Rasmussen, Michael Maeng, Anne Kaltoft, Per Thayssen, Henning Kelbaek, Hans Henrik Tilsted, Ulrik Abildgaard, Evald Høj Christiansen, Thomas Engstrøm, Lars Romer Krusell, Jan Ravkilde, Peter Riis Hansen, Knud Nørregaard Hansen, Steen Zabell Abildstrøm, Jens Aarøe, Jan Skov Jensen, Steen Dalby Kristensen, Hans Erik Bøtker, Morten Madsen, Søren Paaske JohnsenLisette Okkels Jensen, Henrik Toft Sørensen, Leif Thuesen, Jens Flensted Lassen, SORT OUT III study group

Medicinsk Afdeling GLO

185 Citationer (Scopus)

Abstract

In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	375
Udgave nummer	9720
Sider (fra-til)	1090-9
Antal sider	10
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(10)60208-5
Status	Udgivet - 27 mar. 2010

Adgang til dokumentet

10.1016/S0140-6736(10)60208-5

Citationsformater

Rasmussen, K., Maeng, M., Kaltoft, A., Thayssen, P., Kelbaek, H., Tilsted, H. H., Abildgaard, U., Christiansen, E. H., Engstrøm, T., Krusell, L. R., Ravkilde, J., Hansen, P. R., Hansen, K. N., Abildstrøm, S. Z., Aarøe, J., Jensen, J. S., Kristensen, S. D., Bøtker, H. E., Madsen, M., ... SORT OUT III study group (2010). Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet, 375(9720), 1090-9. https://doi.org/10.1016/S0140-6736(10)60208-5

Rasmussen, K, Maeng, M, Kaltoft, A, Thayssen, P, Kelbaek, H, Tilsted, HH, Abildgaard, U, Christiansen, EH, Engstrøm, T, Krusell, LR, Ravkilde, J, Hansen, PR, Hansen, KN, Abildstrøm, SZ, Aarøe, J, Jensen, JS, Kristensen, SD, Bøtker, HE, Madsen, M, Johnsen, SP, Jensen, LO, Sørensen, HT, Thuesen, L, Lassen, JF & SORT OUT III study group 2010, 'Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial', Lancet, bind 375, nr. 9720, s. 1090-9. https://doi.org/10.1016/S0140-6736(10)60208-5

@article{ec5790ef800c43f4b0a33a1891546190,

title = "Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial",

abstract = "In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up.",

author = "Klaus Rasmussen and Michael Maeng and Anne Kaltoft and Per Thayssen and Henning Kelbaek and Tilsted, {Hans Henrik} and Ulrik Abildgaard and Christiansen, {Evald H{\o}j} and Thomas Engstr{\o}m and Krusell, {Lars Romer} and Jan Ravkilde and Hansen, {Peter Riis} and Hansen, {Knud N{\o}rregaard} and Abildstr{\o}m, {Steen Zabell} and Jens Aar{\o}e and Jensen, {Jan Skov} and Kristensen, {Steen Dalby} and B{\o}tker, {Hans Erik} and Morten Madsen and Johnsen, {S{\o}ren Paaske} and Jensen, {Lisette Okkels} and S{\o}rensen, {Henrik Toft} and Leif Thuesen and Lassen, {Jens Flensted} and {SORT OUT III study group}",

year = "2010",

month = mar,

day = "27",

doi = "10.1016/S0140-6736(10)60208-5",

language = "English",

volume = "375",

pages = "1090--9",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "9720",

}

TY - JOUR

T1 - Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial

AU - Rasmussen, Klaus

AU - Maeng, Michael

AU - Kaltoft, Anne

AU - Thayssen, Per

AU - Kelbaek, Henning

AU - Tilsted, Hans Henrik

AU - Abildgaard, Ulrik

AU - Christiansen, Evald Høj

AU - Engstrøm, Thomas

AU - Krusell, Lars Romer

AU - Ravkilde, Jan

AU - Hansen, Peter Riis

AU - Hansen, Knud Nørregaard

AU - Abildstrøm, Steen Zabell

AU - Aarøe, Jens

AU - Jensen, Jan Skov

AU - Kristensen, Steen Dalby

AU - Bøtker, Hans Erik

AU - Madsen, Morten

AU - Johnsen, Søren Paaske

AU - Jensen, Lisette Okkels

AU - Sørensen, Henrik Toft

AU - Thuesen, Leif

AU - Lassen, Jens Flensted

AU - SORT OUT III study group

PY - 2010/3/27

Y1 - 2010/3/27

N2 - In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up.

AB - In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up.

U2 - 10.1016/S0140-6736(10)60208-5

DO - 10.1016/S0140-6736(10)60208-5

M3 - Journal article

C2 - 20231034

SN - 0140-6736

VL - 375

SP - 1090

EP - 1099

JO - Lancet

JF - Lancet

IS - 9720

ER -

Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater